Update on the Distribution of Donated Remdesivir from Gilead Sciences
May 10, 2020
On May 1, 2020, the FDA granted an Emergency Use Authorization (EUA) for Gilead’s remdesivir for the treatment of COVID-19. Gilead has been working closely with the U.S. government on preparations to donate and distribute remdesivir across the country to treat critical COVID-19 patients, and will work with AmerisourceBergen as the sole distributor for the donated remdesivir.
The U.S. government is coordinating the distribution of remdesivir by determining how much drug each state will receive. Gilead and AmerisourceBergen are working under the guidance of the federal and state governments and state public health departments for the distribution of remdesivir. Neither Gilead nor AmerisourceBergen are deciding which hospitals will receive remdesivir.
For further information, please see HHS’ May 9, 2020 announcement, available at https://www.hhs.gov/about/news/2020/05/09/hhs-ships-first-doses-of-donated-remdesivir-for-hospitalized-patients-with-covid-19.html.
Retail and specialty pharmacies are not eligible to receive donated remdesivir.
- For questions about the distribution of remdesivir, call the national remdesivir donation inquiry line at 877-987-4987.
- For information on clinical trials that are testing the use of remdesivir in COVID-19, please visit www.clinicaltrials.gov.
- For additional medical information about remdesivir, please visit https://www.askgileadmedical.com/remdesivir/ or call 1-866-MEDI-GSI (1-866-633-4474) Monday – Friday, 6am – 4pm PT.
We will update this message as additional information becomes available.
A letter to our customers from Heather Zenk, SVP, Secure Supply Chain Operations
As we continue to work our way through this challenging time, I simply want to thank you for entrusting me with the privilege of working with you and your dedicated teams as we all get through this together.
AmerisourceBergen and our global pharmaceutical healthcare businesses are monitoring the ongoing spread of the novel COVID-19 coronavirus.
The health, safety and well-being of our associates is a top priority during this global pandemic.
We're supporting our front-line associates during COVID-19 with:
Weekly bonus incentive pay
Back-up dependent care program
Enhanced cleaning protocol including EPA-approved disinfectants and additional support from third-party cleaners
Enhanced paid time off policy for associates needing to self-quarantine or care for family members